Drug Assistance Program

The goal of the Alabama AIDS Drug Assistance Program (ADAP) is to reduce associated morbidity/mortality among HIV infected persons by delaying the progression of HIV disease through prevention and treatment of HIV complications.

Guidance for COVID-19 and Persons with HIV

Persons with HIV Should:

• Maintain on-hand at least a 30-day supply—and ideally a 90-day supply—of antiretroviral (ARV) drugs and other medications.
• Talk to their pharmacists and/or healthcare providers about changing to mail order delivery of medications when possible.
• Persons for whom a regimen switch is planned should consider delaying the switch until close follow-up and monitoring are possible.
• Lopinavir/ritonavir (LPV/r) has been used as an off-label treatment for patients with COVID-19 and clinical trials are underway globally. If protease inhibitors (PIs) are not already part of a person’s ARV regimen, their regimen should not be changed to include a PI to prevent or treat COVID-19, except in the context of a clinical trial and in consultation with an HIV specialist. In a small open-label trial, 199 hospitalized patients with COVID-19 were randomized to either 14 days of LPV/r plus standard of care or standard of care alone. No statistically significant difference was seen between the two groups, with regards to time to clinical improvement or mortality.¹

Note: During the COVID-19 Response, 90-day prescriptions are available for all uninsured clients utilizing ADAP formulary and for all insured clients based on their BCBS insurance plans allowable until June 30, 2020.  

Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32187464.

ADAP and Part B Services Annual Report

The ADAP and Part B Services Annual Report, 2018, is now available. This report reflects the clients actively enrolled in ADAP as of December 31, 2018, and clients receiving Part B core medical and support services during 2018. ADAP and Part B services clients achieve optimal health outcomes at a higher rate than all persons living with HIV in Alabama, with the majority of ADAP and Part B services clients already surpassing or approaching the National HIV/AIDS Strategy (NHAS) 2020 indicators of 90 percent retention in HIV medical care and 80 percent viral suppression.

Alabama AIDS Drug Assistance Program (ADAP) Satisfaction Survey

The ADAP Satisfaction Survey is designed to help improve ADAP medication services. The survey should take approximately 5-10 minutes to complete, and answers and comments will remain anonymous. Take the survey.

ADAP Patient Activity Open Enrollment

Updated: March 27, 2020
Active: 565
Medcap: 83

Forms

Alabama's Ryan White Part B Program Eligibility Standards (November 2019)

Alabama RWHAP Part B Income Eligibility Guidelines (January 2020)

Alabama RWHAP Part B Annual Certification/Recertification Schedule (July 2017)

BCBS Authorization for Disclosure of Protected Health Information (January 2017)

BCBS Eligibility Coordination of Benefits (November 2015)

BCBS Dental Binding Arbitration (January 2020)

Ryan White Part B Program Authorization for Release of Protected Health Information (June 2019)

ADAP-Enhanced Plus Enrollment Guidance (February 2019)

Alabama ADAP Formulary Listed Alphabetically (April 2019)

Alabama ADAP Formulary Listed by Drug Class (April 2019)

ADAP Manifestación de certificación del cliente (January 2009)

Fuzeon Pre-Approval Checklist (October 2014)

Procrit Pre-Approval Form (October 2014)

National Monitoring Standards Basics (May 2013)

Universal Monitoring Standards (May 2013)

National Monitoring Standards Ryan White Part B Grantees: Program Part B (May 2013)

Contact Us

Alabama AIDS Drug Assistance Program
Office of HIV Prevention and Care
Alabama Department of Public Health
The RSA Tower
201 Monroe Street, Suite 1400
Montgomery, AL 36104
Phone: 1-866-574-9964
Fax: (334) 206-6221

Page last updated: March 27, 2020